Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1:12:691200.
doi: 10.3389/fphar.2021.691200. eCollection 2021.

Comparative Efficacy and Acceptability of Anti-inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis

Affiliations

Comparative Efficacy and Acceptability of Anti-inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis

Xiaoyi Hang et al. Front Pharmacol. .

Abstract

Background: With the growing importance of research about the association between neuroinflammation and major depressive disorder (MDD), anti-inflammatory agents have been used as a new antidepressant therapy in clinical practice. We conducted a network meta-analysis (NMA) with up-to-date evidence to compare different anti-inflammatory agents for improving the treatment of MDD patients. Methods: To identify eligible randomized clinical trials, four databases (i.e, the Cochrane Library, Web of Science, PubMed and Embase) were searched from inception date to May 31, 2020. Anti-inflammatory agents were defined as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, cytokine inhibitors, statins, pioglitazone, minocycline, N-acetylcysteine (NAC) and omega-3 fatty acid (Omega-3 FA). The main outcomes of this NMA were efficacy, acceptability and remission rate. Risk ratio (RR) was adopted for dichotomous outcomes, and the confidence interval (CI) was set at 95%. STATA 14.0 and R 3.6.3 were used to conduct the NMA. The study protocol was registered with PROSPERO (CRD42020182531). Results: A total of 39 studies, involving 2871 participants, were included in quantitative data synthesis. For efficacy, NSAIDs (RR=0.50, 95%CI: 0.26-0.73) and pioglitazone (RR=0.45, 95%CI: 0.20-0.84) were more favorable than placebo. With respect to acceptability, NSAIDs were more acceptable than placebo (RR=0.89, 95%CI: 0.77-0.99) and minocycline (RR=1.22, 95%CI: 1.03-1.49). For remission, NSAIDs were more superior than placebo (RR=0.48, 95%CI: 0.27-0.79) and Omega-3 FA (RR=2.01, 95%CI: 1.09-3.90), while NACs were more favorable than placebo (RR=0.39, 95%CI: 0.13-0.99). Based on the surface under the cumulative ranking curve (SUCRA) value, corticosteroids (0.86) were the best anti-inflammatory agent for MDD patients in terms of efficacy, but the head-to-head comparisons for the efficacy of glucocorticoids and other agents were not statistically significant. As for acceptability, NSAIDs (0.81) were much better than other anti-inflammatory agents. Besides, NAC (0.80) was the best anti-inflammatory agent in the terms of remission. Conclusions: In summary, we found that corticosteroids were more superior than other agents in terms of efficacy according to the SUCRA value. However, this result must be interpreted with caution because the head-to-head comparisons for the efficacy of glucocorticoids and other agents did not reach statistical significance. NSAIDs were recommended for acceptability and NAC for remission rate.

Keywords: acceptability; anti-inflammatory; efficacy; major depressive disorder; network meta-analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Literature search and selection.
FIGURE 2
FIGURE 2
(A) Network map for efficacy. (B) Network map for acceptability. (C) Network map for remission. Display of the network of eligible studies for efficacy (A) and acceptability (B) and remission (C). The width of the line indicates the number of trials comparing two agents. The size of the node indicates the number of MDD patients randomized to a particular agent. NSAIDs: non-steroidal anti-inflammatory drugs; NACs: N-acetylcysteines; Omega-3 FA: omega-3 fatty acid.

Similar articles

Cited by

References

    1. Abbasi S. H., Hosseini F., Modabbernia A., Ashrafi M., Akhondzadeh S. (2012). Effect of Celecoxib Add-On Treatment on Symptoms and Serum IL-6 Concentrations in Patients with Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Study. J. Affect Disord., 141(null), 308–314. 10.1016/j.jad.2012.03.033 - DOI - PubMed
    1. Adzic M., Brkic Z., Mitic M., Francija E., Jovicic M. J., Radulovic J., et al. (2018). Therapeutic Strategies for Treatment of Inflammation-Related Depression. Curr. Neuropharmacol, 16(2), 176–209. 10.2174/1570159X15666170828163048 - DOI - PMC - PubMed
    1. Akhondzadeh S., Jafari S., Raisi F., Nasehi A. A., Ghoreishi A., Salehi B., et al. (2009). Clinical Trial of Adjunctive Celecoxib Treatment in Patients with Major Depression: a Double Blind and Placebo Controlled Trial. Depress. Anxiety, 26(7), 607–611. 10.1002/da.20589 - DOI - PubMed
    1. Al-Harbi K. S. (2012). Treatment-resistant Depression: Therapeutic Trends, Challenges, and Future Directions. Patient Prefer Adherence, 6(undefined), 369–388. 10.2147/PPA.S29716 - DOI - PMC - PubMed
    1. Arana G. W., Santos A. B., Laraia M. T., McLeod-Bryant S., Beale M. D., Rames L. J., et al. (1995). Dexamethasone for the Treatment of Depression: a Randomized, Placebo-Controlled, Double-Blind Trial. Am. J. Psychiatry, 152(2), 265–267. 10.1176/ajp.152.2.265 - DOI - PubMed